浩欧博(688656.SH):MM09舌下喷雾剂III期临床试验完成首批受试者入组

智通财经
Sep 24

智通财经APP讯,浩欧博(688656.SH)公告,公司与Inmunotek公司签订独家排他战略合作协议,由公司独家将Inmunotek公司旗下Oraltek®(欧脱克®)系列脱敏药品引进中国市场,开展欧脱克系列脱敏药品的国内销售和注册,以实施公司在国内脱敏药领域新业务,打通过敏行业上下游业务,有助于解决因没有相关药物治疗严重影响过敏诊疗行业发展、制约过敏检测业务发展的问题,满足过敏患者的诊疗需求。

近日,公司收到全资子公司上海浩欧博生物医药有限责任公司(简称“上海浩欧博”)通知,由上海浩欧博与Inmunotek公司联合申报的脱敏药MM09舌下喷雾剂III期临床试验成功完成首批受试者入组给药。此外,依托广东省药品监督管理局“港澳药械通”政策支持,猫毛、狗毛及屋尘螨/粉尘螨三款单品已顺利获得“粤港澳大湾区内地临床急需进口港澳药品批件”。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10